房颤是临床常见的心律失常，与死亡、中风和周围血管栓塞的风险增加有关。导管消融（CA）是治疗房颤患者的有效方法。然而，许多研究报道了CA后不理想的治疗结果，因为房颤复发率经常保持较高水平。因此，有必要提前识别易于复发并需要CA后进行抗炎和/或抗心律失常治疗的患者。近年来，预测房颤和CA后房颤复发已成为临床实践的热点。许多生物标志物（如B型利钠肽、N末端前脑钠肽前体、高敏C反应蛋白等）已被确认为预测CA后房颤和房颤复发风险的标志物。尽管这些标志物已被证明可以预测CA后的房颤和房颤复发，但目前还没有相关指南来指示哪些标志物具有绝对的预测价值。因此，寻找可有效和准确预测房颤消融后的房颤复发的适当指标对于为每个患者提供最佳治疗非常重要。这些指标仍需要进一步探索。糖类抗原125（CA-125）是一种适用于卵巢恶性肿瘤筛查、诊断和监测的肿瘤标志物，在心力衰竭患者中已得到广泛研究。近年来，CA-125在房颤中的作用得到了广泛研究，本文对此进行了综述。其广泛的可用性和低成本为其快速应用提供了额外的优势。本文综述了CA-125在房颤患者中的作用。版权所有©2023 Elsevier B.V。保留所有权利。

Atrial fibrillation is the most common arrhythmia in clinical settings. It is associated with an increased risk of death, stroke, and peripheral vascular embolism. Catheter ablation (CA) is an effective treatment for patients with AF. However, many studies have reported suboptimal outcomes, as AF recurrence rates often remain high after CA. Therefore, there is a need for early identification of patients who are prone to recurrence and require anti-inflammatory and/or antiarrhythmic treatment after CA. In recent years, Prediction of AF and AF recurrence after CA has become a hot topic in clinical practice. A lot of biomarkers (Such as B-type natriuretic peptide, N-terminal pro-BNP, high sensitivity C reactive protein etc.) have been identified as markers for predicting the risk of AF and AF recurrence after CA. Although these markers have been shown to predict AF and AF recurrence after CA, there are currently no relevant guidelines to indicate which of these markers have absolute predictive value. Therefore, Finding the appropriate indicators that can efficiently and accurately predict AF recurrence after AF ablation is important to provide the best treatment for each patient. These indicators still need exploration. Carbohydrate antigen 125 (CA-125) is a tumor marker suitable for the screening, diagnosis, and monitoring of ovarian malignant tumors. It has been widely studied in patients with heart failure. In recent years, the role of CA-125 in AF has been widely studied, and we provide a review in this article. It is wide availability and low cost provide additional advantages for its rapid implementation. This article reviews the role of CA-125 in patients with atrial fibrillation.Copyright © 2023 Elsevier B.V. All rights reserved.